AstraZeneca: ovarian cancer drug gets European approval
(CercleFinance.com) - The European Medicines Agency (EMA) has approved AstraZeneca's Lynparza tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, the British drugmaker said on Tuesday.
The EU approval was based on two randomised trials which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed ovarian cancer patients compared to placebo, AstraZeneca said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The EU approval was based on two randomised trials which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed ovarian cancer patients compared to placebo, AstraZeneca said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.